MiNK Therapeutics, Inc.
INKT
$11.71
-$0.25-2.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.14% | 45.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.68% | 45.62% | |||
| Operating Income | 13.68% | -45.62% | |||
| Income Before Tax | 31.86% | -53.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 31.86% | -53.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.86% | -53.17% | |||
| EBIT | 13.68% | -45.62% | |||
| EBITDA | 13.73% | -46.64% | |||
| EPS Basic | 38.93% | -52.51% | |||
| Normalized Basic EPS | 33.19% | -48.44% | |||
| EPS Diluted | 38.93% | -52.51% | |||
| Normalized Diluted EPS | 33.19% | -48.44% | |||
| Average Basic Shares Outstanding | 11.58% | 0.43% | |||
| Average Diluted Shares Outstanding | 11.58% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||